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ABSTRACT 
 
 
TRPV1 MRNA IS DIFFERENTIALLY EXPRESSED IN DIFFERENT VERTEBRAL 
 
LEVELS OF RAT DORSAL ROOT GANGLIA FOLLOWING 
 
SCIATIC NERVE INJURY 
 
 
 
 
 
By 
 
Bree Zeyzus Johns 
 
May 2009 
 
 
 
Thesis Supervised by John A. Pollock, Ph.D. 
 
Transient Receptor Potential Vanilloid 1 plays an important role in the pain 
pathway.  TRPV1 is expressed in primary afferent nociceptors and acts as a transducer 
for noxious stimuli; including capsaicin, toxins and noxious heat.  TRPV1 protein 
expression increases in inflammatory and neuropathic pain models, but transcriptional 
regulation of TRPV1 remains unclear.  In the present study, TRPV1 mRNA levels were 
measured in Dorsal Root Ganglia pertaining to the third, fourth and fifth vertebral levels 
of the lumbar spine following chronic constriction injury of the sciatic nerve in rats.  
TRPV1 mRNA levels are shown to increase in lumbar dorsal root ganglia in response to 
sciatic nerve injury.  Moreover, the magnitude of change in TRPV1 mRNA level varies 
with dorsal root ganglia level.  These novel findings show that TRPV1 mRNA levels are 
regulated in response to chronic nerve injury, and strengthen interest in this channel as a 
specific target for pain therapy. 
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Chapter 1 
 
 
INTRODUCTION 
 
 
1.1  The impact of pain on society: The Pain Paradox 
Pain is an epidemic which affects an estimated 50 million Americans and costs 
approximately US$61 billion in lost productivity and healthcare expenses per annum [1, 
2].  This number rises each year as the occurrence of serious diseases such as heart 
disease, AIDS, diabetes and arthritis also rise.  Despite the substantial investment in 
pharmaceutical research, common pain treatments have changed little over the last 
several decades. New therapies for treating pain are needed.   
Among the milieu of drug options presently available, two broad classes of drugs 
stand out; the opioids and the non-steroidal anti-inflammatory drugs (NSAIDS).  Opiod 
drugs are commonly chosen as the first-line treatment for patients suffering from severe, 
acute pain or from chronic pain associated with a long-term illness.  Pure opioid agonists, 
like oxycodone and morphine, principally function to increase analgesia [3].  It is 
contended that they exert their action by binding all opioid receptors in the central 
nervous system (CNS), and thus, are associated with a plethora of undesirable 
pharmacological affects such as constipation, respiratory depression, and sleeplessness, 
among others [3].  Tolerance and withdrawal occur and can pose serious clinical 
problems for patients using opioid drugs for pain therapy.   
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NSAIDS are typically used to treat moderate acute pain, inflammation, and 
redness or are used in conjunction with opioids to treat chronic pain [4].  NSAIDS are 
non-narcotic analgesics that exert their function in the peripheral nervous system by 
inhibiting cyclooxegenase (COX) enzymes.  COX-1 and COX-2 catalyze the production 
of prostaglandins and other inflammatory and pain mediators. Similar to opioids, 
NSAIDS are broadcast non-specifically throughout the body and, thus, are also 
associated with many serious side affects [4].    
Aside from the potential pharmacological complications, the efficacy of the 
presently used therapies is under question.  Opioids, NSAIDS, anti-epileptics and 
tricyclic antidepressants fail to produce sustainable relief from chronic pain [1, 5].  This 
so-called ‘pain paradox’ exemplifies the need for novel analgesic drug development.  
Before our society can face this clinical challenge, however, we must expand our 
knowledge of the molecular basis of pain.  The purpose of this study is to help bridge this 
gap between the basic biology of pain and a clinical application.  
 
 
1.2  The physiology of pain and nociception 
Metazoans are continuously bombarded with stimuli.  These stimuli encounter the 
peripheral receptors of sensory nerves, which innervate both tissues to the exterior and 
those found inside the body.  It is a requirement of an organism’s peripheral and central 
nervous systems to process and coordinate the information in order to respond 
accordingly.  More specifically, it is essential to differentiate among stimuli that are 
potentially tissue-damaging and those that are innocuous [6].  Higher eukaryotes have 
evolved a protective mechanism in response to noxious stimuli that involves the 
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generation of a highly unpleasant sensation.  Once perceived by the brain, the painful 
sensation causes the organism to take actions that will minimize exposure to the 
threatening stimulus [7].  It is the action of nociceptors that initiates this protective alarm 
bell. 
In 1903, Charles Sherrington first coined the term nociception and defined it as 
the ability of specialized neurons, which he later defined as nociceptive nerves or 
nociceptors, in the peripheral nervous system (PNS) to sense a potentially damaging 
stimulus [8,9].    In order to function purely as an alarm bell for harmful stimuli, 
nociceptors have a high threshold and only respond to stimuli with sufficient energy to be 
tissue-damaging [10].  Some nociceptors can be thinly myelinated, but the majority are 
un-myelinated, slow propagating C fibers [10].   
Nociceptors are a type of primary sensory neuron that are attuned to painful 
stimuli. The cell bodies of nociceptors are found in dorsal and trigeminal ganglia and 
have one major extension, which bifurcates into two projections; one extending to the 
skin of the body and face, the mouth and the tongue, and the other into the CNS where it 
synapses on nociceptive second order neurons [10,11].  Consequently, the nociceptor has 
four functional components; the peripheral terminal which innervates the skin of the 
target tissue and contains ion channels that transduce the injurious stimulus, the axon 
which propagates the action potential to the central nervous system, the cell body which 
is housed in dorsal root ganglia (DRG), and the central terminal, where information is 
transferred to higher order neurons in the CNS (Fig 1A) [10].   
Upon activation of nociceptive ion channels by a noxious stimulus, the peripheral 
terminals become depolarized.  The influx of Na + and Ca2+ causes the interior of the 
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neuron to become more positive.  If the stimulus is strong enough and the influx of 
cations is sufficient to surpass the voltage threshold of the neuron, an action potential is 
initiated at the axon hillock.  The action potential is propagated along the length of the 
axon until it reaches the central terminal.  At the central terminal, substance P and/or 
other neuropeptides are released, and these bind their receptors located in the plasma 
membrane of the synapsing second order neuron (Fig 1B).  The signal is transferred to 
higher brain centers, where it is ultimately integrated and perceived as pain. 
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Figure 1.  Nociceptor Structure and Mechanism.  
 
(A)  Structure of a nociceptor.  Peripheral terminal innervates the skin and 
transduces the noxious stimulus.  Axon propagates the action potential.  Cell 
body is located in the Dorsal Root Ganglion (DRG).  Central terminal 
transfers the signal to higher order neurons. 
(B)  Mechanism of nociception.  Ion channels involved in the transduction of 
noxious stimuli depolarize the interior of the peripheral terminal causing a 
generator potential.  An action potential is initiated at the axon hillock, and is 
propagated to the central terminal by way of the axon.  Central terminal 
releases neuropeptides in response, which either excite or inhibit the 
synapsing second order nociceptive neuron. 
 
Figure from reference 10. 
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1.3  The Transient Receptor Potential (TRP) protein superfamily 
 A number of ion channels have been identified that are involved in the 
nociceptive pathway.  Among them is a class of proteins called the Transient Receptor 
Potential (TRP) proteins.  TRP proteins are generally defined as cation-permeable ion 
channels that share the same general membrane topology; six-transmembrane (6TM) 
polypeptide units flanked by an N- and C-terminus, a conserved TRP domain and a pore-
loop between segments 5 and 6 [12,13].  Aside from sharing this general function and 
structure, TRP channels are otherwise highly diverse in their pharmacology and 
physiology.   
In the human genome, 28 TRP genes have been identified [6].  These genes are 
further classified into 6 subfamilies based on sequence homology: TRPA, TRPC, TRPM, 
TRPML, TRPP and TRPV [14].  The nomenclature was unified by members of the TRP 
Nomenclature Committee [15].  Members of the TRPA subfamily were named for their 
structural similarity to the ankyrin protein. The TRPC, or TRP-Canonical, subfamily is so 
named because these proteins are the most highly related to the prototype Drosophila trp 
[16, 17].  The TRPV subfamily is named after the original designation for its first 
mammalian member, Vanilloid Receptor 1.  The TRPM family was named for its 
founding member, melastatin (MLSN), which is encoded by a predicted tumor-
suppressor gene [18].  TRPML is named for the human mucolipin 1 protein.  Lastly, 
TRPP is so named for its founding member, PKD2 [19]. 
TRP protein channels are activated by a variety of different physical stimuli; to 
include noxious, chemical, thermo- and mechanostimuli [14].  Following their activation, 
TRP channels transduce the signal like all primary sensory neurons.  An influx of cations 
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crosses the plasma membrane, subsequently raising the intracellular Ca2+ and Na+ 
concentrations.  This depolarization event alters the voltage properties of the neuron such 
that a threshold value is reached, and an action potential is propagated to the CNS.  The 
signal is sent to higher brain centers where it is integrated with other signals, and is 
ultimately perceived [14].   
A subset of TRP channels are expressed in primary afferent nociceptors and in 
pain sensing ganglia where they act as transducers for physical and noxious stimuli 
(Table 1) [5].  These pain-sensing TRPs, which include TRPV1-4, TRPA1 and TRPM8, 
are highly diverse in their sequence homology, modalities, regulation and expression; yet, 
there is evidence to support their unique involvement in the generation of pain [5, 20-29]. 
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Table 1.  Pain Sensing TRP Proteins. 
 
**Information for table from references 5 and 6.  Abbreviations: Dorsal Root Ganglia (DRG), Trigeminal 
Ganglia (TG), nitric oxide (NO). 
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1.4   Transient Receptor Potential Vanilloid 1 (TRPV1) 
Among the pain-sensing TRPs, TRPV1 (also called vanilloid receptor 1, VR1 or 
the capsaicin receptor) is the most well characterized member. It was the first receptor of 
the TRPV family cloned [20], and is so named because of it’s activation by the pungent 
ingredient in hot peppers, capsaicin.  Aside from activation by exogenous vanilloid 
ligands, this polymodal ion channel is also activated by noxious heat (≥43°), endogenous 
lipid signaling molecules (eicosanoids), and low pH [19, 30, and 31].  More recently, 
TRPV1’s activation by spider and jellyfish toxins [21, 22], camphor [31] and allicin [32, 
33] has also been reported.  TRPV1 was originally described in small to medium-
diameter neurons in dorsal root, trigeminal and nodose ganglia [20, 31].  It has since been 
identified in other non-neural tissues, yet it is most highly expressed in sensory neurons 
[34].   
The role of the TRPV1 channel in models of acute pain is well established [23-25, 
35-37].  Capsaicin induces nocifensor, or pain-like, behaviors and hyperalgesia 
(reduction of pain threshold) in rodents and humans [35, 36].  Studies involving TRPV1 
knock-down and knock-out phenotypes support a role for TRPV1 in the development of 
pain [23-25].  Of particular interest, trpv1(-/-) mice experience a reduced response to 
noxious heat and pungent vanilloid compounds following injection of tissue-damaging 
preparations; including complete Freund’s adjuvant (CFA) and carrageenan into the 
plantar surface of the hind paw.   CFA is a preparation of dried mycobacterium and 
carrageenan is a red seaweed extract.  TRPV1 antagonists, including SB-705498 and 
A425619, have proven successful in pre-clinical trials using acute inflammatory pain 
models [38, 39]. 
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 In models of neuropathic pain, where a pathological condition arises from a nerve 
or group of nerves, it is contended that TRPV1 is a key mediator.  In rat chronic pain 
models involving complete ligation of the L5 spinal nerve and partial ligation of the 
sciatic nerve, undamaged neurons reportedly experience an increase in TRPV1 protein 
expression [40].  Spinal TRPV1 protein levels ipsilateral to the nerve injury increase 
significantly following chronic constriction injury of the sciatic nerve [41].  A sustained 
increase in TRPV1 protein levels is also observed in rat DRG following injection of 
complete Freund’s adjuvant (CFA) into the plantar surface of the hind paw [42].  The 
contribution of TRPV1 to pathophysiological conditions such as irritable bowel 
syndrome [43,44], acute pancreatitis [45,46], asthma and arthritis [47] is complex and 
likely explained by excessive release of neuropeptides from TRPV1-expressing neurons, 
which promotes inflammation [45].   
There is evidence that TRPV1 protein expression but not mRNA levels increase 
in dorsal root ganglia (DRG) 7 days after production of chronic constriction injury on the 
sciatic nerve in rats [27,42].  These studies assayed for changes in mRNA level from 
combined DRG dissected from multiple vertebral levels; however, afferent contributions 
from the sciatic nerve to lumbar DRG are not equal (Figure 2) [48, 49].  Moreover, 
animals with CCI reportedly experience maximum pain sensitivity 12 days post-surgery, 
and thus, it is worth investigating gene expression at a later time point. Given variations 
of the previous studies and the lack of knowledge in this regard, the following hypotheses 
were formed: (1) TRPV1 mRNA levels in DRG are altered in response to sciatic nerve 
injury, (2) the magnitude of change in TRPV1 mRNA level varies with DRG level due to 
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varying afferent contributions from the sciatic nerve, and (3) changes in TRPV1 gene 
expression may be time-dependent.   
Here I report the novel results of my thesis work. TRPV1 mRNA levels in lumbar 
Dorsal Root Ganglia are increased in response to chronic constriction injury-induced 
neuropathic pain.  Additionally, I also demonstrate that the magnitude of change in 
TRPV1 transcript level varies with Dorsal Root Ganglia level. 
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Figure 2.  Rat Neural Anatomy. 
 
Dorsal view of rat spinal cord and associated neural structures.   
Cell bodies of neurons in Dorsal Root Ganglia (DRG) pertaining to the third, fourth 
and fifth vertebral level of the lumbar spine project axons that give rise to spinal 
nerves.  These spinal nerves join to form the sciatic nerve at the mid-thigh level.   L4 
and L5 DRG contain 98-99% of the somata of neurons projecting to the sciatic nerve, 
and L3 only contains 1.2% of total somata.  Contribution of L6 to the sciatic nerve is 
variable (dotted line), and at most represents 0.4% of total somata.  Autoclips for 
wound closure are in place at the level of mid-thigh following chronic constriction 
injury of the sciatic nerve (refer to methods). 
 
Artwork kindly provided by Mr. Robert Hoggard. 
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Chapter 2 
 
 
MATERIALS AND METHODS 
 
 
2.1  Production of the chronic constriction injury 
This study was approved by the Institutional Animal Care and Use Committee of 
Duquesne University.  A total of 18 adult male Sprague-Dawley rats (Hilltop Lab 
Animals, Inc., Scottdale, PA, 170g) were used for the experiments.   
The chronic constriction injury (CCI) method, as described by Bennett and Xie, 
was used to induce the neuropathic pain state [50]. This chronic pain model is used in the 
laboratory of committee member, Dr. David Somers, to mimic chronic regional pain 
syndrome II (CPSII) in humans [51-54].  CPSII is a pain syndrome that develops often in 
an extremity following injury to a peripheral nerve.  In the rat, this procedure causes the 
hind paw on the operated side to develop a reduced pain threshold to thermal and 
mechanical stimulation, as well as postural indications of ongoing pain.  Dr. Somers is 
well established with this procedure, and provided training of all the skills necessary to 
reproduce it independently. 
Rats were deeply anesthetized with sodium pentobarbital (50mg/kg) by 
intraperitoneal injection, and the anesthesia was assessed by both a tail pinch and the leg 
withdrawal reflex.  Additional doses (approximately 6mg/kg) of the anesthetic were 
supplemented as needed.  Briefly, the right thigh of each animal was opened to expose 
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the sciatic nerve.  The right sciatic nerve was selected purely for technical reasons.  Four 
4.0 chromic gut sutures were tied loosely around the sciatic nerve such that the nerve was 
not overly constricted under the ligature and perfusion of the nerve distal to the ligature 
site was not altered [50].  Special care was taken to space the ligatures 1mm apart from 
one another to avoid over-constriction of the nerve in a single area, as this could inhibit 
propagation of pain signals to the CNS.  The wound was closed in layers, with 4.0 silk 
sutures to close the muscle and autoclips to close the skin.  Following surgery, weight 
measurements of the chronic pain animals were measured bi-weekly to ensure the 
animals’ health and well being.  Photographs of the CCI surgical procedure can be found 
in Figure 3 (A-E). 
Two groups of control rats were used in this study; a uni-lateral sham-operation 
group (sciatic nerve exposure without ligation) and an un-operated group.  The latter only 
received anesthetic.   
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Figure 3.  Chronic Constriction Injury Surgery. 
 
(A)  Pre-surgery; Anesthetized rat with surgical area, right thigh, shaved and 
sterilized (beta-iodine solution). 
(B)  Surgery; Sciatic nerve exposed. 
(C)  Post-surgery; Rat still under anesthesia following surgery.  Skin superficial to 
wound closed with autoclips. 
(D)  Rat sciatic nerve with four 4.0 chromic gut sutures in place (see box inset).  The 
lack of perfusion to the nerve and surrounding muscle that is evident is a result of 
the rat’s post-mortem status. 
(E)  Sketch of rat sciatic nerve with four sutures in place.  The spinal cord and the 
L5 spinal nerve intersecting with L4 are shown.  Intersection of these nerves forms 
the sciatic nerve at mid-thigh level. 
 
Photographs A-C kindly provided by Karl Andersen. 
Artwork (E) kindly provided by Mr. Robert Hoggard. 
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2.2  Pain assessments 
All rats underwent bi-lateral sensory testing for mechanical allodynia (pain 
sensitivity to a non-painful, mechanical stimulus) and thermal hyperalgesia, both of 
which are well documented symptoms of CCI-induced neuropathic pain [50].  Baseline 
assessments were performed on all rats the same day as the CCI and sham operations, but 
prior to the commencement of these procedures.  To evaluate the development of chronic 
pain over time, the tests were then repeated on all rat subjects 8 days post-surgery and 
then again 11 days post-surgery.  A timeline of this experimental design and the pain 
assessment equipment are represented in Figure 4 (A-C). 
Mechanical pain threshold was assessed by applying calibrated Semmes-
Weinstein monofilaments [52, 55, and 56] to the plantar surface of the animals’ hind 
paw, specifically in the cutaneous region that is innervated exclusively by the sciatic 
nerve [52, 57].  Briefly, rats were placed on a metal grid that was covered with a 
Plexiglas lid (Figure 4B).  The filaments (0.41, 1.2, 3.63, 8.51, 15.13g) were applied in 
ascending order, from the lowest caliber filament to the highest, and the total number of 
paw withdrawals from each stimulus was recorded for both the left and right hind paw.  
Each paw received a total of 10 pushes from each filament (two trials separated by 5 min, 
5 applications per trial, 3 s per each application).  The testing was terminated when the 
largest caliber filament was tested or when the rat withdrew from all 10 pushes for a 
single filament. 
The linear regression method was used to estimate each rat’s 50% withdrawal 
threshold, or the force (g) at which the rat withdrew a paw 5 of 10 total pushes.  If the rat 
failed to respond to any filaments used, 15.13g was recorded as the 50% withdrawal 
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threshold (WT) [52].  On three occasions, an animal withdrew its paw from a caliber with 
intermediate thickness in the middle of a test series, and then the same rat did not respond 
whatsoever to the thickest (15.13g) caliber applied thereafter.  This situation is often a 
display of the rat’s anxiety to the test, and does not reflect a positive, painful response.  
When encountered, the zero strategy that has been used by Dr. Somers was used.  The 
zero representing no paw withdraws from the thickest caliber filament was eliminated 
from the analysis altogether, and the regression was run on the filaments of less force that 
were applied before the first response.  Thus, the 50% withdraw threshold is placed over 
the value of the filaments where the animal most likely withdrew.  Although I did not test 
for the reliability of this strategy, Dr. Somers has repeated the behavior and regression 
test over time and found it to be an extremely reliable method.  A normalized difference 
score was calculated for each rat at each time point using the following formula: 
 
Normalized 50% withdrawal threshold (WT) = Post-Surgery (50% WT right paw 
– 50% WT left paw) – Baseline (50% WT right paw – 50% WT left paw). 
 
 
All normalized withdrawal thresholds for a given treatment group (un-operated control, 
sham-operated control, CCI) at each time point were averaged, and the Kruskal-Wallis 1-
way ANOVA by Ranks Test was used to compare the means (P ≤ 0.05).  The Kruskal-
Wallis value from each comparison was compared to the critical value of the chi-squared 
distribution with 1 degree of freedom and alpha = 0.05.  This value was determined to be 
3.84. 
Thermal pain threshold was assessed by withdraw latency from a radiant heat 
source.  Rats were placed on a temperature controlled plexi-glass surface in a plexi-glass 
cubicle (Figure 4C).  The heat source was a projector bulb from a slide projector that is 
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attached to a timer and focused through a fixed diameter aperture.  After habituation for a 
period of 5 minutes, radiant heat was applied to the plantar surface of both the left and 
right hind paws of the chronic constriction injury rats, the sham-operated and un-operated 
control rats. Stimulus onset activated a timer that was controlled by a photocell that was 
positioned to receive reflected light from the hind paw.  Paw withdrawal interrupted the 
photocell’s light and automatically stopped the timer.  Each paw received a total of five 
irradiations, with five minutes separating each irradiation.  The latency to withdraw in 
hundredths of a second was recorded.  Twenty seconds was the maximum irradiation 
time in order to prevent the glass from reaching a temperature that could burn the 
animals’ hind paws.  The five latency measurements obtained for each paw were 
averaged in order to obtain a mean latency.  Normalized withdrawal latency was 
calculated for each rat at each time point using the following formula: 
 
Normalized Withdrawal (WD) Latency = Post-Surgery (WD latency right paw – 
WD latency left paw) – Baseline (WD latency right paw – WD latency left paw). 
 
 
All normalized withdrawal latencies for a given treatment group (un-operated control, 
sham control, CCI) at each time point were averaged, and the Kruskal-Wallis 1-way 
ANOVA by Ranks Test was used to compare the means. 
 Nocifensor behaviors such as guarding the affected paw from the test surface and 
excessive paw licking and lifting directly following application of each stimulus were 
noted for all rats in the study. A table was created of the number of animals that 
responded with a pain response at least one time while performing the mechanical and 
thermal pain assessments.  Guarding refers to prolonged contact avoidance between the 
affected (right) hind paw and the test surface.  Guarding was observed in rat subjects 
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during the rest period (5 minutes) between trials of each test session.  Rats displayed 
guarding by lying on their left side with the affected right paw in a protected position 
against their flank.  Excessive right paw licking refers to the rat withdrawing a paw 
quickly from a poke (mechanical) or the heat (thermal) and bringing the paw immediately 
to their mouth to lick it.  Paw lifting was recorded directly following the stimulus, and 
was defined as withdrawing the right paw from the stimulus and holding it for a 
prolonged period of time (5-10 sec) before lowering the paw to the test surface. 
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Figure 4.  Animal Work. 
 
(A)  Experimental design; Baseline pain assessments were performed on un-
operated controls, sham controls and CCI rats on day 0 prior to CCI and sham 
surgeries.  Pain assessments were repeated 8 and 11 days post-surgery.  Dorsal root 
ganglia were dissected from half of the animals (3 CCI, 3 sham-operated controls, 
3 un-operated controls) 9 days post-surgery, and DRG from the remaining half 
were dissected on day 12.  
(B)  Mechanical pain assessment; Rats positioned on metal grid.  Mechanical 
allodynia was tested by poking (Semmes-Weinstein monofilaments) the plantar 
surface of the rats’ hind paws from beneath the grid.   
(C)  Thermal pain assessment; Rats positioned on temperature-controlled plexi-
glass.  Thermal hyperalgesia is tested by applying radiant heat (seen below right 
rat) to the plantar surface of hind paws.  Withdraw latency measured in ms.   
 
Photographs kindly provided by Karl Andersen. 
A 
B C 
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2.3  Dorsal Root Ganglia dissection 
Ipsilateral and contralateral lumbar Dorsal Root Ganglia (DRG) 3-5 were 
dissected from 3 CCI rats, 3 sham-operated and 3 un-operated control rats 9 days post-
surgery via laminectomy.  Briefly, animals were anesthetized with sodium pentobarbital 
(50mg/kg) intraperitoneally.  A mid-line incision was made dorsally from the level of the 
cervical vertebrae to the sacrum.  The spinous and lateral processes of the lumbar 
vertebrae were exposed, and the spinous processes were clipped with medical Rongeurs.  
The dorsal lumbar vertebrae were flattened with a Dremel drill, and the spinal column 
was carefully opened, exposing the spinal cord and DRG (Fig 5).  Ganglia were rapidly 
removed and submerged immediately into RNAlater solution (Qiagen).  Twelve days 
post-surgery, DRG were collected in the same fashion from the remaining rats (3 CCI, 3 
sham-operated, 3 un-operated).  Rats were terminated via cervical dislocation after 
completion of DRG extraction.  DRG samples were stored at -80°C.  Refer to Figure 2 
for a drawing of the rat neural anatomy. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                                                                                           B. Zeyzus Johns 
22 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A B C 
Figure 5.  Rat Dorsal Root Ganglia Dissection. 
 
(A) Rat dorsal spinal column exposed.  Lumbar vertebrae are shaved. 
(B) Rat dorsal spinal column clipped to expose underlying spinal cord. 
(C) Rat spinal cord with laterally positioned Dorsal Root Ganglia (L3-L6) exposed. 
 
Photographs kindly provided by Karl Andersen. 
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2.4  RNA isolation and quantification 
Total RNA was extracted from Sprague-Dawley rat Dorsal Root Ganglia (DRG) 
using the RNeasy kit with QIAShredder columns provided by Qiagen.  RNA samples 
underwent DNaseI treatment and were reverse transcribed using a poly-dT primer 
(DNaseI, Super Script III RT, Invitrogen).  Rat DRG cDNA samples were stored at -20°C 
until further use. 
Quantitative PCR analysis was performed on the DRG cDNA samples in 
quadruplicate and was repeated at least once (Rotorgene2000 software, Corbett).  cDNA 
was amplified with Express Sybr GreenER (Invitrogen) and the following cycling 
parameters were used:  50°C  UDG incubation (2 Min), 95°C Hot start (2 Min), 35 cycles 
of 95°C (20 sec), 68°C (30 sec), 65°C (60 sec).  Samples were prepared on ice in flat cap 
0.2mL PCR tubes, and the total reaction volume was 20µL.  Ultra-pure molecular 
biology grade water was used.  Gene and species-specific primer pairs consisted of: 
 
GAPDH forward (5’-ggctcatgaccacagtccatg-3’) and  
GAPDH reverse (5’-gccatgaggtccaccacc-3’) (GenBank accession no. NM_017008), 
TRPV1 forward (5’-ctatccaggaagttcaccgaatg-3’) and  
TRPV1 reverse  (5’- atccctcggaagaagaagtagactc-3’) (GenBank accession no. 
NM_031982) (Table 2).   
 
The “Noise Slope Correct” analysis tool was used for all reactions in order to 
minimize background fluorescence.  Melt curve analysis was performed for all QPCR 
reactions to verify that each primer set amplified only one major product.  Relative 
TRPV1 mRNA expression in chronic constriction injury rats was analyzed using the 
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comparative Ct method with GAPDH as the endogenous control [58, 59].   (See Results 
section “TRPV1 mRNA quantification” for description).  In accordance with this method, 
primer efficiencies were determined similar for analysis, with a difference in efficiency 
not exceeding 5%.   
Amplified cDNAs were run on 2.5% agarose gels (1x buffer TAE) to verify 
GAPDH and TRPV1 amplicon lengths.  A standard ethidium bromide-staining protocol 
was used.  Ethidium bromide content did not exceed 6% of the total gel volume.  Small 
(35mL) gels were run at 75V for 85 minutes, medium (50mL) gels were run at 75V for 
200 minutes, and large (80mL) gels ran at 90V for 280 minutes. 
 
2.5   Statistical analysis 
All statistical tests were performed using SPSS software.  Assumptions of 
ANOVA were met as indicated by Mauchly’s Test of Sphericity and Levine’s Test for 
Equality of Variances.  Significance of the F statistic was defined as p ≤ 0.05.   
TRPV1 mRNA levels in right (ipsilateral to the nerve injury) DRG of CCI rats 
was compared to right DRG of control (pooled) rats by performing a 1-Way ANOVA 
with treatment as the between-subjects factor.  Each level of the DRG was analyzed 
separately.  Analysis of TRPV1 mRNA levels in left DRG of CCI rats compared to left 
DRG of the pooled control rats was performed the same way.   
Statistical analysis of TRPV1 mRNA levels in the DRG was performed by a 2-
Way Repeated Measures ANOVA for each vertebral level (L3, L4, L5).  The within 
subjects factor was side of the spinal cord (left versus right DRG).   The between-
subjects-factor was defined as the surgical condition: CCI or combined sham and un-
operated controls.   
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Lastly, TRPV1 mRNA levels were compared between DRG L3, L4 and L5 (both 
right and left) of CCI rats by Repeated Measures ANOVA with.  The within subjects 
factor was level of DRG (L3, L4 and L5). The between-subjects-factor was defined as the 
surgical condition: CCI or combined sham and un-operated controls.   
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Table 2.  Primer Sequences for GAPDH and TRPV1. 
 
**GenBank Accession Numbers: NM_017008 (GAPDH), NM_031982 (TRPV1). 
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2.6  Restriction enzyme digestion 
Because the Sybr Green probe can inhibit the complete digestion of amplified 
products with restriction enzymes, GAPDH and TRPV1 were amplified from rat DRG 
cDNA by standard PCR.  Samples were prepared on ice in flat cap 0.2mL PCR tubes, and 
the total reaction volume was 20µL.  Ultra-pure molecular biology grade water was used.   
Manual 5 Prime Hot MasterMix (5 Prime) was used in place of the Express Sybr 
GreenER mastermix (Invitrogen).  Rat DRG cDNA was amplified in the Eppendorf 
Mastercycler using the same GAPDH and TRPV1 primer sets as those used for QPCR 
studies (Table 2).  The following cycling parameters were used:  95°C Hot start (2 Min), 
35 cycles of 95°C (20 sec), 68°C (30 sec), 65°C (60 sec). 
Following amplification, cDNAs were run on 2.5% agarose gels as described in 
section 2.4.  The cDNA fragments were gel extracted and purified (QiaQuick Gel 
Extraction Kit, Qiagen).   GAPDH fragments were directly verified by restriction enzyme 
digestion (GAPDH: BtgI), while TRPV1 fragments were re-amplified in order to increase 
the template concentration for the digestion reaction (TRPV1: Tsp45I; enzymes supplied 
by NEB).  After the second round of amplification and prior to restriction enzyme 
digestion, TRPV1 cDNA was run on a 2.5% agarose gel and gel purified to ensure purity. 
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Chapter 3 
 
 
RESULTS 
 
 
3.1   Production of the chronic constriction injury 
 
 
As early as 1 day post-operative, CCI rats presented with typical neuropathic 
characteristics [50].  While walking and standing, the CCI rats applied minimal weight to 
the affected hind limb and the toes were ventroflexed and close together instead of 
dorsiflexed with toe spreading, which normally accompany such actions.  As the 
experiment progressed, weight bearing avoidance became more evident and limping was 
common.  Some rats even dragged the affected hind limb behind them while walking 11 
days post-CCI surgery.   A reduction in the width of the plantar surface of the right hind 
paw was also observed on day 11, which is suggestive of muscle atrophy [50]. 
 
3.2   Mechanical allodynia 
Chronic constriction injury rats exhibited nocifensor behavior in response to 
calibrated monofilaments at both day 8 and day 11 post operative indicative of 
mechanical allodynia (Fig 6).  The mean normalized 50% withdrawal threshold of 
chronic constriction injury rats was significantly more negative than that observed in the 
un-operated controls at both post-operative time points (Kruskal-Wallis One-Way 
ANOVA by Ranks:  K-W = 4.47,  p = 0.035 at day 8 post-surgery; K-W = 3.8, p = 0.042 
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at day 11 post-surgery).  There was no difference in mean normalized 50% withdrawal 
threshold between the chronic constriction injury rats and the sham control rats at day 8 
or day 11 post-surgery:  K-W = 1.052, p = 0.305 at day 8 post-surgery;  K-W = 2.4, p = 
0.121 at day 11 post-surgery. Similarly, there was no difference in the mean normalized 
50% withdrawal threshold between the un-operated and sham-operated control rats at day 
8 or day 11:  K-W = 1.83, p = 0.176 at day 8 post-surgery;  K-W = 0, p = 1.0 at day 11 
post-surgery.  
Nocifensor behaviors were also recorded for each rat during each test session.  
Because the recording of these observations was done on multiple rat subjects 
simultaneously, these studies were not rigorously performed and the results represent 
preliminary data.  The number of CCI rats, sham controls and un-operated controls that 
exhibited each behavior (guarding, paw licking and paw lifting) was recorded.  Guarding 
and paw lifting were only observed in CCI rats at day 8 and day 11 post-operative (Table 
3).   Excessive paw licking was most frequently observed in the CCI rats (Table 3).  
Generalized muscle weakness suggestive of muscle atrophy was also observed in 
CCI rats, as their right hind paw would slip through the wires of the mesh testing surface 
[50].   
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Figure 6.  Mechanical Allodynia in the Right Hind Paw. 
 
Bars represent the mean ± standard error of the mean (SEM) normalized 
50% withdrawal threshold from calibrated Semmes-Weinstein 
monofilaments (g) for each of the treatment groups; un-operated control, 
sham-operated control, and chronic constriction injury (CCI).  The more 
negative a mean difference score, the lower the pain threshold in the right 
hind paw.  *Significant difference from un-operated control rats (Kruskal-
Wallis 1-way ANOVA by ranks; P≤0.05).  Un-operated and sham-operated 
control rats did not differ in normalized pain thresholds at day 8 or day 11 
post-operative.  Sample size representing each mean indicated on the 
graph. 
 
 6  3 
   6   6  3  3 
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3.3   Thermal hyperalgesia 
Thermal hyperalgesia in chronic constriction injury rats was analyzed by 
determining the withdraw latency from a radiant heat source. Chronic constriction injury 
rats did not differ from either control group in their withdraw latency from heat (Kruskal-
Wallis 1-Way ANOVA by ranks) (Figure 7).  At 8 days post-operative, the mean 
normalized withdrawal latencies (pain score) calculated for CCI rats was no different 
than that calculated for either the un-operated control rats or the sham-operated rats:   
K-W value = 0.23, p = 0.631; K-W value = 0.92, p = 0.34 for comparison to un-operated 
and sham-operated animals, respectively.  Similarly, at 11 days post-operative, there was 
no difference between the normalized difference scores for CCI rats and either the un-
operated control rats or the sham-operated rats:  K-W = 1.19, p = 0.28; K-W = 0.43, p = 
0.52 for comparison to un-operated and sham-operated animals, respectively.  There was 
also no difference between the pain scores calculated for the un-operated and sham-
operated control groups at day 8 or day 11:  K-W = 0.32, p = 0.57; K-W = 0.43,  
p = 0.51 for day 8 and day 11, respectively.  Based on this analysis, the CCI animals did 
not experience thermal hyperalgesia at day 8 or day 11.   
Although the CCI rats did not test positive for thermal hyperalgesia, their pain 
behaviors recorded during this assessment provide evidence of heightened pain 
sensitivity in the right paw as compared to the left.  Similar to that observed during the 
mechanical pain test, only the CCI rats would guard their painful right paw by laying on 
their left side in the test cubicle with their right hind paw in a protected position against 
their flank.  Paw lifting was only observed in CCI rats at day 8 and day 11 post-operative 
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and excessive paw licking was more frequently observed in CCI rats 11 days post-
operative  (Table 3).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.  Absence of Thermal Hyperalgesia in the Right 
Hind Paw. 
 
Bars represent the mean ± standard error of the mean (SEM) normalized 
withdrawal latency from radiant heat for each of the treatment groups; un-
operated control, sham-operated control, and chronic constriction injury 
(CCI).  The more negative a mean value, the lower the pain threshold in 
the right hind paws.    Un-operated control, sham-operated control and CCI 
rats did not differ in normalized pain thresholds at day 8 or day 11 post-
operative.  Sample size representing each mean indicated on the graph. 
 
 6   6 
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Table 3.  Nocifensor Behaviors Recorded During the Mechanical and 
Thermal Pain Assessments. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
** Data represented as the number of animals that responded at least one time in each treatment group. 
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3.4 Confirmation of the amplification of GAPDH and TRPV1 by 
restriction enzyme digestion 
 
PCR amplified GAPDH and TRPV1 cDNAs were digested with restriction 
enzymes in order to verify amplified products.  The results are shown in Figure 8.  The 
Tsp45I enzyme cuts the GAPDH amplicon into two asymmetric fragments with lengths 
332bp and 136bp (Figure 8A).  The 486bp uncut amplicon remains in the no-enzyme-
control lanes (lanes 5 and 8) and to a lesser extent in the experimental lanes (lanes 3, 4 
and 6, 7).  The 332bp cut fragment can be seen in the experimental lanes only.  
Insufficient template concentration is responsible for the absence of the 136bp fragment. 
The BtgI restriction enzyme cuts the 386bp full-length TRPV1 amplicon into two 
fragments of non-equal lengths; 253bp and 133bp (Figure 8B).  Faint bands representing 
the 253bp fragment are observed in the experimental lanes only (lanes 3-8), and un-
digested fragments of length 386bp can be seen in the no-enzyme-control lanes (lanes 9, 
10).  Although TRPV1 cDNA was amplified twice, the template concentration was not 
sufficient to observe the 133bp fragment.   
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Figure 8.  Restriction Enzyme Digested GAPDH and TRPV1. 
 
(A)  Agarose gel (2.5%) of digested GAPDH amplicon.  Lane 1: 100bp DNA 
Step Ladder, Lane 2: 25bp DNA Step Ladder, Lane 3,4,6,7: restriction enzyme 
digested TRPV1 cDNA; box inset of digested GAPDH cDNA fragment (332bp) 
and un-digested (468bp), Lane 5,8: no-enzyme-controls; box inset of un-
digested GAPDH cDNA (468bp). 
(B)  Agarose gel (2.5%) of digested TRPV1 amplicon.  Lane 1: 100bp DNA 
Step Ladder, Lane 2: 25bp DNA Step Ladder, Lane 3-8: restriction enzyme 
digested TRPV1 cDNA; box inset of digested TRPV1 cDNA fragment (253bp), 
Lane 9,10: no-enzyme-controls; box inset of un-digested TRPV1 cDNA 
(386bp).  Adjusted brightness/contrast in Adobe Photoshop (v5.02). 
 
Data collected by Alex Ruiz. 
A B 
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3.5 TRPV1 mRNA quantification 
TRPV1 mRNA levels in DRG were examined by quantitative PCR and the 
comparative Ct method [58, 59]. This method is based on the fact that the difference in 
threshold cycles (∆Ct) between the gene of interest and a reference gene is proportional 
to the relative mRNA level of the gene of interest (Fig 9A, B).  Threshold cycle (Ct) was 
the cycle number at which fluorescence crosses a threshold set by the user. Threshold 
was set at 10-2.5 arbitrary fluorescence units, which samples during the log-linear 
amplification phase, for all samples tested.   
 For each DRG sample, quantitative PCR was performed in quadruplicate and 
repeated once at minimum.  The resultant Ct values from the four replicates were 
averaged, and a ∆Ct value was calculated as the difference between the average Ct of a 
GAPDH mRNA sample and the average Ct of a TRPV1 sample.  This calculation is 
represented in the following formula: 
 
∆Ct = (mean TRPV1 Ct) – (mean GAPDH Ct)   for a DRG mRNA sample. 
 
 
A smaller ∆Ct indicates an increase in TRPV1 mRNA.  The ∆Ct values for each 
treatment group (CCI, sham-operated control, un-operated control) were averaged, and 
their means compared using SPSS statistical software as described in the methods.   
GAPDH mRNA levels were similar in CCI, sham-operated and un-operated control rats 
at day 9 and day 12 post-operative with a maximum variation of ±2 cycles.  Because 
there was no difference in pain scores for the un-operated and sham-operated control 
groups from the pain assessments, the resultant ∆Ct values from these two groups were 
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pooled.  Thus, the mean TRPV1 mRNA level from control rats includes pooled values 
from the un-operated and sham-operated control rats.   
The ∆∆Ct values were calculated as the difference between the ∆Ct from a 
control mRNA sample and the ∆Ct from a CCI mRNA sample.  The ∆Ct from each CCI 
mRNA sample was compared to each of the ∆Ct values from the sham and un-operated 
control mRNA samples.   This calculation is represented in the following formula: 
 
∆∆Ct = (∆Ct from a control rat DRG) – (∆Ct from a CCI rat DRG). 
 
 
A positive ∆ ∆Ct value indicates an increase in TRPV1 mRNA levels in CCI DRG 
compared to control (unaffected) DRG.  The ∆∆Ct values for each treatment group (CCI 
and pooled controls) were transformed to fold changes in TRPV1 mRNA levels using the 
following formula: 
 
Fold Change = 2(∆∆Ct) with standard error of the mean = 2(∆∆Ct ± Std dev) . 
 
 
The resultant fold changes were averaged and graphed to compare differences in 
normalized TRPV1 transcript levels between different DRG spinal levels (L3, L4 and 
L5).   
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Figure 9.  Quantitative PCR Data. 
 
(A)  Standard quantitative PCR plot generated by amplification of GAPDH (the 
endogenous reference gene) and TRPV1 from mRNA extracted from L5 DRG of a 
control rat.  The difference in cycle threshold (∆Ct) is 6.7. 
(B)  Standard quantitative PCR plot generated by amplification of GAPDH and 
TRPV1 from mRNA extracted from L5 DRG of a CCI rat.  The ∆Ct is 5.9, almost 
1 full cycle less than the control ∆Ct.  This equates to almost double the amount of 
starting TRPV1 transcript in CCI DRG compared to the control DRG. 
 
Each fluorescence curve represents quadruplicate QPCR reactions. 
A B 
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3.6   TRPV1 mRNA levels 12 days post-surgery 
Here we report that following chronic constriction injury (CCI) of the sciatic 
nerve, TRPV1 mRNA levels in ipsilateral (right) Dorsal Root Ganglia (DRG) increased 
(Figure 10).  We assayed for changes in TRPV1 mRNA levels in response to sciatic 
nerve injury at DRG levels L3, L4 and L5 due to varying afferent contributions from the 
sciatic nerve [48, 49].  Relative to right DRG from control rats, TRPV1 mRNA levels are 
elevated at all levels of the DRG in CCI rats (Figure 10A).  Differences correspond to an 
increase in relative TRPV1 mRNA expression of 2.6%, 3.1% and 10% in right DRG 
from CCI rats as compared to controls for L3, L4 and L5, respectively.  These differences 
were not statistically different:  L3:  F1,8 = 0.25,  p = 0.63; L4:  F1,8 = 0.2, p = 0.67; L5:  
F1,8 = 1.67, p = 0.24. 
As predicted, there was no difference in TRPV1 mRNA levels in left DRG of CCI 
rats compared to left DRG of pooled controls (Figure 10B).  L3:  F1,7 = 0.01, p = 0.92; 
L4:   F1,8  = 0.09, p = 0.77; L5:  F1,8 = 0.76, p = 0.41. 
 Within CCI animals, TRPV1 transcript levels were higher in the DRG from the 
side ipsilateral to the nerve injury (right DRG) compared to the side contralateral to the 
nerve injury at 12 days post-operative (Figure 10C).  L3 DRG increased by 3.3%, and L4 
and L5 DRG experienced a 5.8 and 8.4 mean percent increase, respectively, relative to 
left DRG at the same levels.   These differences between the left and right DRG were not 
statistically significant.  L3:  F2,5 = 0.05, p = 0.95; L4:  F2,6 = 0.85, p = 0.47; L5:  F2,6 = 
4.29, p = 0.07. 
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Figure 10.  Relative TRPV1 mRNA Levels 12 Days Post-CCI 
Surgery. 
 
(A)  TRPV1 mRNA levels were increased non-significantly in DRG ipsilateral to 
the nerve injury at all levels in CCI rats compared to ipsilateral DRG from pooled 
controls.  (See text for results of statistical tests). 
N=6 ∆Ct values for each control, N=3 ∆Ct values for each CCI mean represented 
mean represented. 
(B)  TRPV1 mRNA levels did not differ in DRG contralateral to the nerve injury in 
CCI rats compared to contralateral DRG from pooled controls.   
N=6 ∆Ct values for each control, N=3 ∆Ct values for each CCI mean represented 
mean represented. 
(C) TRPV1 mRNA was increased non-significantly in the DRG ipsilateral to the 
nerve injury at all levels compared to contralateral DRG.   
N=3 ∆Ct values for each mean represented. 
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3.7   TRPV1 mRNA levels 9 days post-surgery 
Differences in TRPV1 transcript levels were also examined 9 days post-surgery 
(Figure 11).  Relative to right DRG from control rats, there was no difference in TRPV1 
mRNA levels for L4 and L5 DRG of CCI rats.  There was an unexpected increase, 
however, in the TRPV1 transcript level in CCI DRG L3 compared to control DRG L3 
(Figure 11A).  This difference was not statistically different:  L3:  F1,8 = 1.56, p = 0.25; 
L4:  F1,8 = 0.01, p = 0.93; L5:  F1,8 = 0.14, p = 0.72. 
As predicted, there was no difference in TRPV1 mRNA levels in left DRG of CCI 
rats compared to left DRG of pooled controls (Figure 11B):  L3:  F1,8 = 0.61, p = 0.46; 
L4:  F1,8 = 4.75, p = 0.07; L5:  F1,8 = 2.78, p = 0.14. 
Within CCI animals, TRPV1 transcript levels were higher in the DRG from the 
side ipsilateral to the nerve injury (right DRG) compared to the side contralateral to the 
nerve injury (left DRG) at 9 days post-operative (Figure 11C).  These differences were 
not statistically significant:  L3:  F2,6 = 2.83, p = 0.14; L4:  F2,6 = 1.75, p = 0.25; L5:  F2,6 
= 0.97, p = 0.43.    
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Figure 11.  Relative TRPV1 mRNA Levels 9 Days Post-CCI 
Surgery. 
 
(A)  Relative mRNA levels in DRG ipsilateral to the nerve injury from CCI rats 
compared to ipsilateral DRG from pooled controls.  TRPV1 mRNA levels were 
increased non-significantly in ipsilateral DRG at level 3 in CCI rats.  There was 
no difference in TRPV1 mRNA levels in L4 and L5 DRG from controls.  (See 
text for results of statistical tests). 
N=6 ∆Ct values for each control, N=3 ∆Ct values for each CCI mean 
represented.  
(B)  TRPV1 mRNA levels did not differ in DRG contralateral to the nerve injury 
in CCI rats compared to contralateral DRG from pooled controls.   
N=6 ∆Ct values for each control, N=3 ∆Ct values for each CCI mean 
represented.  
(C) TRPV1 mRNA was increased non-significantly in the DRG ipsilateral to the 
nerve injury at all levels compared to contralateral DRG.   
N=3 ∆Ct values for each mean represented. 
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3.8   TRPV1 mRNA levels in different spinal levels of DRG 
 
 
 We also compared TRPV1 mRNA levels in DRG at different spinal levels to 
determine whether the magnitude of TRPV1 gene expression varies with spinal level 
following sciatic nerve injury.  The mRNA levels, when represented as Ct values, were 
not statistically different between DRG 3, 4 and 5 at either day 9 or day 12 post-surgery:  
day 9:  F2,14 = 1.36, p = 0.29; day 12:  F2,14 = 1.45, p = 0.27 (Repeated Measures 
ANOVA).  When normalized to transcript levels in ipsilateral DRG from control rats, 
however, TRPV1 mRNA levels showed a marked increase in L5 DRG ipsilateral to the 
nerve injury 12 days after surgery (Figure 12A).  This difference equates to a 1.6-fold 
increase in TRPV1 mRNA in L5 DRG, almost double the amount found in ipsilateral 
DRG from control animals.  There was no increase (fold change ≤ 1) in relative TRPV1 
transcript levels in L3 and L4 ipsilateral DRG  normalized to DRG from pooled controls:  
L3:  0.5-fold change; L4:  0.4-fold change. 
Within CCI animals, TRPV1 transcript levels were highest in the L5 DRG 
ipsilateral to the nerve injury when normalized to transcript levels in contralateral DRG 
from control rats at the same level 12 days post-surgery (Figure 12B).  This difference 
equates to a 1.5-fold increase in TRPV1 mRNA in L5 DRG.  TRPV1 transcript levels 
normalized to levels in contralateral DRG were not increased in L4 DRG, and there was a 
decrease in transcript levels in L3 DRG:  L3:  -0.1-fold change; L4:  0.8-fold change. 
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A 
Figure 12.  Relative TRPV1 Gene Expression Changes 12 Days 
Post-CCI Surgery. 
 
(A) TRPV1 mRNA levels were 1.6-fold higher in L5 DRG ipsilateral to the 
nerve injury (right) from CCI rats compared to DRG from control rats.  
TRPV1 transcript levels were not increased in L4 and L5 ipsilateral CCI 
DRG. 
N = 18 fold change values for each mean represented. 
 
(B) Within CCI rats, TRPV1 mRNA levels were 1.5-fold higher in L5 DRG 
ipsilateral to the nerve injury (right) compared to contralateral DRG (left).  No 
difference in TRPV1 mRNA levels between ipsilateral and contralateral L4 
DRG.  TRPV1 transcript levels are decreased in ipsilateral DRG 3 compared 
to contralateral DRG 3. 
N = 3 fold change values for each mean represented. 
 
B 
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Differences in TRPV1 transcript levels at different spinal levels of DRG were also 
examined 9 days post-surgery (Figure 13).  When normalized to transcript levels in 
ipsilateral DRG from control rats, TRPV1 mRNA was unexpectedly increased in L3 
ipsilateral DRG of CCI rats 12 days post-surgery (Figure 13A).  This difference equates 
to a 1.5-fold increase in TRPV1 mRNA in L3 DRG.  The mean-fold differences in 
normalized TRPV1 transcript levels for L4 and L5 ipsilateral DRG suggest a possible 
down-regulation (fold change approaching 0 or ≤ 0) in TRPV1 gene expression:  L4:  
0.1-fold change; L5:  -0.3-fold change. 
 Within CCI animals at 9 days post-surgery, TRPV1 transcript levels in ipsilateral 
L5 DRG normalized to transcript levels in contralateral DRG were not increased (Figure 
13B).   
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Figure 13.  Relative TRPV1 Gene Expression Changes 9 
Days Post-CCI Surgery. 
 
(A) TRPV1 mRNA levels were 1.5-fold higher in L3 DRG ipsilateral to 
the nerve injury (right) from CCI rats compared to DRG from control rats.  
TRPV1 transcript levels are decreased in ipsilateral DRG L4 and L5 
compared to ipsilateral control DRG at the same levels. 
N = 18 fold change values for each mean represented. 
 
(B) Within CCI rats, TRPV1 mRNA levels were not increased for DRG 
ipsilateral to the nerve injury (right) compared to contralateral DRG (left) 
in L3, L4 and L5 DRG.   
N = 3 fold change values for each mean represented. 
 
A 
B 
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3.9  Primer efficiency validation 
For the ∆Ct calculation to be valid, it is essential that the amplification 
efficiencies of the gene of interest and the reference gene be similar [58, 59]. GAPDH 
and TRPV1 primer efficiency was assessed by observing how ∆Ct varies with template 
dilution.  A DRG cDNA preparation was diluted over a 2-fold range.  Quantitative PCR 
was performed on each dilution sample with sybr green probe (Express Sybr GreenER, 
Invitrogen) and the primer sets listed in Table 2.  The ∆Ct was determined as the 
difference between the average GAPDH Ct and the average TRPV1 Ct.  The log cDNA 
dilutions were plotted against ∆Ct values.  If the absolute value of the slope is close to 0, 
the primer sets are considered approximately equal, and the ∆Ct calculation can be used 
for relative mRNA quantification.  The slope of the line is less than 0.1 at 0.0245; 
therefore, the assumption that the efficiencies are similar holds true (Figure 14). 
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Figure 14.  Validation of the ∆∆Ct Calculation for mRNA 
Quantification. 
 
(A) Serial 2-fold serial dilutions of cDNA were amplified by quantitative PCR using 
gene-specific primers for GAPDH and TRPV1.  From left to right the diluted cDNA 
preparations are as follows: GAPDH 1:2 (red), 1:4 (blue), 1:8 (black), 1:16 (purple), 
1:32 (green) and TRPV11:2 (red), 1:4 (blue), 1:8 (black), 1:16 (purple), 1:32 (green). 
The ∆Ct (Ct TRPV1-Ct GAPDH) was calculated for each cDNA dilution.   
(B)  Data were fit using least squares linear regression (n=5).  The slope of the line is 
less than 0.1 at 0.0245 and the primer efficiencies are considered similar. 
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3.10 Pair-wise comparisons between TRPV1 gene expression and right 
hind paw allodynia 
 
 
Because each individual rat’s pain behavior and response was expected to be 
variable due to inherent individual differences, the 50% withdrawal threshold and L5 
DRG mRNA levels for all rats terminated on day 12 were compared within each 
individual.  As shown in Table 4, each of the three chronic constriction injury rats had a 
negative normalized difference score, or pain score, indicating mechanical allodynia on 
the day 11 test. Comparing the relative TRPV1 mRNA level in each individual CCI rat to 
that of each of the different control rats reveals an increase in relative transcript levels in 
the CCI rats in the majority of cases.  Moreover, ∆∆Ct values that arise from comparison 
of a CCI to a normal control resulted in the greatest value.  Normal controls were defined 
as those with a pain score of 0, indicating no difference in response to the calibrated 
monofilaments for the left and right paw.   
Although we observe an increase in TRPV1 mRNA in CCI DRG relative to 
controls in the majority of cases, we did not find a correlation between the magnitude of 
pain and mRNA level in ipsilateral DRG.  Only two of the three CCI rats tested 11 days 
post-surgery had substantially negative pain scores (pain score ≤ -7.0).  CCI rat 3 had a 
pain score of only -0.4, and thus was in less pain than CCI rats 1 and 2. 
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Table 4:  Pair-wise Comparisons Between 50% Withdrawal Threshold 
(Mechanical Pain Score) and Relative TRPV1 mRNA Levels in Rats 
with and without Chronic Constriction Injury; Level 5 DRG. 
 
       
 * See Results Section 3.5 for ∆∆Ct  and fold change formulas.  
Positive ∆∆Ct reflects an increase in TRPV1 transcript in CCI DRG relative to control DRG.  Positive fold 
changes representing an increase in TRPV1 mRNA level are represented in bold font. 
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Chapter 4 
 
 
DISCUSSION 
 
 
The TRPV1 ion channel is a modulator of neuropathic pain.  In peripheral nerve 
terminals and in sensory ganglia, TRPV1 protein but not mRNA levels have been 
demonstrated to increase in response to a nerve injury [40, 42].  In this thesis project, 
TRPV1 mRNA levels in ipsilateral and contralateral Dorsal Root Ganglia (DRG) neurons 
were compared at discrete vertebral levels after induction of chronic constriction injury 
(CCI) on the sciatic nerve.   
 
 
4.1 Increased TRPV1 mRNA levels 
The results show that with an increase in mechanical pain sensitivity caused by 
chronic constriction injury, TRPV1 mRNA levels increase 12 days post-surgery.  It was 
determined that the TRPV1 transcript level in L5 DRG on the side of the nerve injury in 
CCI animals is increased compared to the transcript level in L5 DRG on the same side 
(right) in the controls and to both the transcript level in L5 contralateral (left) DRG 
within CCI rats.  We interpret this to mean that TRPV1-expressing neurons in the DRG, 
namely the small diameter C-fibers, are likely producing more TRPV1 transcript in 
response to sciatic nerve injury.  It may also be the case that neuron types that normally 
do not express TRPV1, such as the large-sized DRG somata, are now induced to do so.  
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Induction of TRPV1 protein expression through a phenotypic switch phenomenon is 
evident in similar pain models [40, 60].  Considering that we did not detect any change in 
TRPV1 mRNA levels in contralateral DRG cell bodies, it seems that there is no bilateral 
affect of nerve injury on TRPV1 mRNA levels.   
Our analysis of the increase in TRPV1 mRNA 12 days post-surgery is based on a 
whole tissue analysis.  Implicit is the fact that the change in TRPV1 mRNA level is not 
uniform over the cells in the DRG.  It is documented that only an estimated 10% of the 
neurons in each ganglion express TRPV1 [60].  Rather, individual TRPV1 responsive 
neurons are likely exhibiting substantial increases in mRNA level on a cell by cell basis.  
Given that the TRPV1 transcript level at L5 is 1.6-fold higher in CCI animals than DRG 
from controls, the overall TRPV1 expression is nearly doubling in CCI animals. 
We expect that this increase in TRPV1 mRNA may contribute, in part, to the 
production and maintenance of heightened pain sensitivity.  Regulation of TRPV1 gene 
expression may be occurring in many different ways.  Inflammatory mediators such as 
NGF can initiate p38 protein kinase activity in the DRG, which in turn, activates 
transcription factors such as ATF-2, ELK-1 and CREB to increase transcription [61-63].  
Protein kinases can also increase stability of the TRPV1 message and activate 
translational factors [64].  More TRPV1 channels in the plasma membranes of terminal 
nociceptors decreases the animals’ mechanical and thermal pain threshold [42].  A 
decreased pain threshold leads to an increase in perceived pain.  In this current study, 
heightened pain response typical of mechanical allodynia was only observed for the right 
hind paw of CCI rats, which is consistent with our finding of no bilateral affect of the 
induction of pain on TRPV1 gene expression. 
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4.2 Effect of anatomical DRG level on mRNA expression 
We have demonstrated that the magnitude of the increase in TRPV1 mRNA level 
is affected by anatomical DRG level.  We analyzed TRPV1 mRNA levels at each DRG 
level separately unlike other investigators who pooled RNA from all ipsilateral and 
contralateral DRG for their analysis [27].  It is suggested that 98-99% of the somata of 
primary afferent neurons projecting to the sciatic nerve reside in L4 and L5 DRG of rats, 
while L3 and L6 contribute only 1.2% and 0.4% of the total, respectively [48,49].  
Moreover, TRPV1 is expressed in small to medium diameter sensory neurons [20,60,65].  
This neuron type is found in the greatest relative abundance in L5 DRG [48].  
Considering the differing afferent contributions from the sciatic nerve to ganglia and the 
different combinations of neuron types therein, it is not surprising that others did not find 
a substantial change in TRPV1 mRNA levels after nerve injury.  Although we did not 
survey for mRNA levels in L6 DRG, we would expect no change in TRPV1 gene 
expression as the contribution of the L6 spinal nerve to the sciatic nerve is low (5-10% of 
L5) and highly variable, with some rats having no contribution from L6 (Figure 2) [49].      
To our knowledge, we are providing the first report that shows the effect of 
anatomical DRG level on the degree of increasing TRPV1 gene expression after injury to 
the sciatic nerve. This observation need be considered by other investigators examining 
changing gene expression in similar pain models.  Together, our findings support the 
hypothesis of an injury-induced gene expression mechanism for chronic pain, with 
TRPV1 as a key player in this process.   
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4.3 Analysis of individuals 
In addition to making an assessment of mean pain threshold and mean TRPV1 
mRNA level, we chose to examine pain behavior and mRNA levels in L5 DRG on an 
individual basis. Regardless of a precedent for variable responsiveness, the argument for 
an increase in TRPV1 mRNA is supported by this individual analysis at day 12.  The CCI 
rats exhibit pain behaviors not seen in the controls and, in the majority of cases, have 
higher TRPV1 transcript levels.  The variation in individual ∆∆Ct that we observe was 
expected, and is not unlike typical variation we would expect in humans, as each person’s 
response to the same pain can be unique.  As such, persons suffering from diseases 
associated with neuropathic pain, such as CPSII [66], diabetes [67] or cancer [68] may 
benefit from therapies designed to disrupt the induction of TRPV1 mRNA expression.   
We were not able to demonstrate that the degree of pain measured in the CCI rats 
correlates with an increase in TRPV1 mRNA.  Not all (2 out of 3) of the CCI rats 
assessed on day 11 post-surgery had substantially negative pain scores (-7.3).  Our 
assessment indicates that CCI rat 3 did not experience pain that was very unlike that 
observed for the control rats, with a pain score of only -0.4.  This rat was in less pain, yet 
we determined its relative TRPV1 mRNA level exceeded that of the control rats, even 
those controls with more negative pain scores. Furthermore, even though CCI rat 2 was 
experiencing pain, the amount of TRPV1 transcript measured in L5 DRG did not exceed 
levels in some (2 of the 5) control rats.  These observations, although unexpected, are 
likely due to variability in pain response for the controls.  Attention, attitude and the 
tightness of the ligature are factors that may have led to the failure to represent the 
allodynic state of CCI rat 3. 
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Implicit in this analysis is the idea that given a larger ‘normal’ control group 
sample size (pain score of 0), we can predict an even greater observed pain response and 
change in TRPV1 mRNA both at the level of the individual CCI rat and as a group.   
 
 
4.4 Pain assessments 
The results of the mechanical pain assessment indicate that the CCI rats 
experienced mechanical allodynia at day 8 and day 11 post-operative.  The mean 
normalized difference score (pain score) for the CCI treatment group calculated by 
comparing the total number of withdraws in the right paw to the left paw was 
significantly more negative than the un-operated control group at both day 8 and day 11 
post-surgery (Kruskal-Wallis One-Way ANOVA by Ranks).  We found that the CCI 
group had a more negative pain score than the sham-operated control group; however, the 
difference was not significant at either day 8 or day 11 post-surgery.  This may indicate, 
especially at 8 days post-operative, that the sham operation created a slight pain-like state 
that was detected by poking the rat’s hind paws with the monofilaments, although there is 
no evidence of this in the literature.  On the other hand, the negative pain score may also 
represent variations in the pain response of the control rats to the painful stimulus.  We 
are not the first to report variable responses to a mechanical pain stimulus in un-operated 
or sham-operated control rats.  Analysis of our data directly followed methods used by 
Dr. David Somers.  In his published work, Dr. Somers reports a slightly negative (~-2.0) 
difference score for his un-operated control group 12 days post-operative [52].  The 
inherent variable responsiveness of control groups is magnified in a small sample size 
like that used in this study (n=6 at 8 days post-surgery and n=3 at 12 days post-surgery).   
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The results of the thermal pain assessment do not indicate that the CCI rats 
experienced thermal hyperalgesia at day 8 or day 11 post-operative; yet, it is documented 
elsewhere that rats should have a marked reduction in their thermal pain threshold as 
early as the second post-operative day [50].  The thermal pain assessment tends to be less 
reliable than the mechanical pain assessment, and is subject to more procedural problems.  
For instance, habituating the animals on the heated surface tends to be far more 
problematic than habituation on the metal grid.  The rats experience anxiety that results in 
frequent urination and defecation throughout the test session.  The animals must be 
removed from the plexi-glass surface, and the area must be cleaned thoroughly.  The rats 
are then put back in their testing cubicles and must be habituated again before re-
commencing with the testing.     
Once the rats are relaxed in the testing cubicles, the radiant heat aperture must be 
carefully aligned under their hind paws so that the laser irradiates a specific region of the 
paw pad that is exclusively innervated by the sciatic nerve.  The animal must remain still 
during the irradiation.  At the end of the trial, the administrator must distinguish whether 
the rat displayed a painful response or a non-painful response.  Although special care and 
attention were given to completing this task with reproducible accuracy, it proved rather 
difficult to the un-practiced administrator.  Thus, the failure to accurately measure the 
CCI rats’ hyperalgesic state is likely due to these potential sources of error. As shown in 
Table 3 and Appendix Table 5, CCI rats exhibited nocifensor responses to the thermal 
pain assessment that were not seen in the controls.  Thus, although analysis of difference 
scores did not support thermal hyperalgesia, rat pain-like behaviors observed during the 
test sessions did. 
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4.5 Day 9 post-CCI surgery  
TRPV1 mRNA levels were markedly increased in L3 DRG 9 days post-CCI 
surgery.  Although unexpected, our observation may be a genuine effect that is 
meaningful to the development of the pain syndrome and/or to the increase that was 
observed in L4 and L5 DRG 12 days post surgery. Although afferent contributions from 
the sciatic nerve to L3 DRG are reportedly minimal [48, 49], it has been shown that 
ligation of the L3-L5 spinal fibers in the sciatic nerve can influence the central axon 
fibers in the dorsal horn of the spinal cord.  One study that used the CCI pain model 
found that labeling neurons on the uninjured, contralateral side of the nerve injury 
revealed a connection between L3-L6 spinal segments [69].  Lissaur’s tract, or the 
dorsolateral fasciculus, is a bundle of association fibers that connect different segments of 
the posterior horn of the spinal cord. It is possible that axons that travel in Lissaur’s tract 
may be responsible for the anatomical connections between the different spinal segments 
in CCI rats [69].   
Since sensory nerve fibers extend between different segments of the spinal cord, it 
is possible that intersegmental changes can occur, and that these changes can alter the 
Dorsal Root Ganglia pertaining to these spinal levels. Others have noted intersegmental 
changes that occur with the CCI pain model.  CCI-induced sciatic nerve lesion produces a 
significant increase in spinal cord metabolic activity in lumbar regions L1-5 [70].  
Following CCI, primary afferent nociceptors undergo reorganization that results in A-β 
fibers sprouting to the third segment (L3) of the spinal cord [71].  Nerve sprouting was 
detectable in CCI rats 1 week following surgery, was at its maximum 2 weeks post-
surgery, and persisted for 6 months or more.  These temporal events closely match 
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clinical, mechanically-evoked pain responses of patients suffering from nerve injury [71].  
At 9 days post-CCI surgery, we observe an increase in TRPV1 mRNA levels in L3 right 
DRG of CCI rats relative to L3 right DRG in the controls that is not seen in L4 or L5 
DRG.  We believe this increase may be explained by the reorganization of primary 
afferent fibers to the L3 spinal segment, and that these events may be responsible, in part, 
for central sensitization. 
It may also be the case that the L3 phenomenon was caused by a surgical mishap.  
While performing the chronic constriction injury surgery, it was observed that some 
animals differ anatomically in their sciatic nerve branching structure.  More specifically, 
differences in the presence or absence of a branch destined for muscle at mid-thigh levels 
were observed.  Care was taken by the investigator to keep the nerve area surrounding 
this branch point clear. It is possible that a surgical knot was tied too closely to the branch 
or, conversely, that after closing the surgical wound, a knot may have shifted such that 
the branch point was constricted.  Three sensory branches innervate the skin and/or 
muscle at the level of the middle thigh; the lateral sural, the peroneal and the tibial nerves 
[48]. All three of these branches contain neurons whose cell bodies are found in L3 DRG 
[48].  Constriction of the branch point as described may have produced a painful state in 
the muscle and skin of the thigh, and thus altered TRPV1 mRNA levels in L3 DRG.   
 
4.6 Temporal relationship between nerve injury and TRPV1 mRNA 
levels 
 
At 12 days post-surgery, TRPV1 transcript levels were substantially elevated in 
ipsilateral L5 DRG and only moderately elevated in L4 DRG of CCI rats compared to 
transcript levels from control rat DRG.  Chronic constriction injury of the sciatic nerve 
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did not affect the amount of transcript, however, at 9 days post-surgery at these DRG 
levels.  Similar to the effect of time on the complex inter-segmental spinal interactions 
that may be affecting events in L3 DRG, it is possible that a temporal relationship exists 
between the initial nerve injury and the induction of increased TRPV1 transcript levels in 
L4 and L5 DRG.  One study that examined TRPV1 transcript levels separately in L4 and 
L5 DRG 7 days post-operative supports our finding of no change in transcript levels at an 
earlier time [42].  We, however, are the first to examine TRPV1 mRNA levels in rat 
DRG using the CCI model at a later time.   
The pain literature supports a precedent for time-dependent changes in CCI-
induced events [71, 72, 73, 74, and 75].  Different mechanisms are involved at different 
stages of pain development, where early mechanisms involving pro-inflammatory 
cytokines like TNF-alpha and IL-6 are responsible for activating other pro-inflammatory 
and pro-nociceptive mediators important for peripheral sensitization.  Over time, these 
early processes begin to operate in conjunction with longer-term gene expression 
mechanisms that appear necessary for the maintenance of neuropathic pain.  Our findings 
support the notion that transcriptional regulation of TRPV1, like many other molecules 
cited, is time-dependent.  This may suggest that increasing TRPV1 protein levels are 
necessary for peripheral sensitization and the development of acute pain, while increasing 
TRPV1 mRNA levels is more important for central sensitization and the maintenance of 
chronic pain [40, 41, and 42]. 
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Chapter 5 
 
 
FUTURE DIRECTIONS 
 
 
5.1 Elucidate neuronal cell population information 
Quantitative PCR results show unequivocally that TRPV1 transcript levels 
increase in ipsilateral DRG 12 days after injury to the sciatic nerve.   Information about 
the DRG cell population responsible for this increase, however, remains unknown.  Back-
labeling and in situ hybridization experiments would be useful procedures to address this 
unknown.  We have successfully used a retrograde axonal tracer, DiD, to label neurons 
that project from the skin of the plantar surface of the rat’s hind paw to the DRG.  
Fluorescent in situ hybridization (FISH) in DRG using a probe specific for TRPV1 
mRNA could be used to identify the cells that express TRPV1.  Using confocal 
microscopy, the images produced from the back labeling and FISH experiments can be 
superimposed to identify a TRPV1-expressing cell population with axonal extensions that 
project into the sciatic nerve and into the affected area of the hind paw.  
By performing these experiments in control and CCI, we would elucidate useful 
information about changes in Dorsal Root Ganglia physiology in response to nerve 
injury.  We could determine the percentage of DRG neurons 1) that normally express 
TRPV1 mRNA and receive afferents from the sciatic nerve and 2) that normally do not 
express TRPV1 mRNA but are induced to do so following CCI.  It has been documented 
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that TRPV1 protein expression increases in the somata of DRG neurons that normally do 
not express it [40].  It is conceivable that a changing gene expression phenotype is 
driving the observed phenotypic protein switch.   
Chronic constriction injury is a partial nerve injury that results in the death of 
some axons that pass through the lesion site.  Other axons retain the ability to transmit 
electrical activity and perform axonal transport through the lesion site [71].  Data 
surrounding the roles of injured and uninjured axons in neuropathic pain remain 
controversial.  It is documented that TRPV1 protein expression decreases in injured 
DRG; yet, uninjured DRG neurons experience an increase in protein levels after CCI or 
similar pain models [42, 71].  By probing for both TRPV1 and neuronal injury marker 
transcript, we could determine whether the increase in TRPV1 mRNA level is 
exclusively reserved for either injured or uninjured axons.   
All of the proposed experiments should be performed on separate DRG from their 
respective vertebral levels.   
 
5.2 Analysis of other TRP genes and splice variants 
The differential expression of other TRP genes that are known to function in the 
pain pathway has yet to be explored in rat DRG.  Among them, Transient Receptor 
Potential Mellastatin 8 (TRPM8) has attracted interest for its involvement in the sensory 
transduction of innocuous cold, inflammatory pain, menthol and other cooling agents [5, 
6].  Transient Receptor Potential Ankyrin 1, likewise, has a known involvement in 
inflammatory pain, and is activated by cold (T≤18°C), mustard oil and the pungent 
chemical in garlic [5, 6].  It is documented that TRPM8 and TRPA1 mRNA levels 
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increase in rat Dorsal Root Ganglia by chronic constriction injury of the sciatic nerve 
[26].  Analysis of expression; however, was performed on pooled RNA from L4, L5 and 
L6 DRG.  It was determined in the present study that anatomical DRG level affects the 
magnitude of the increase in TRPV1 mRNA levels.  As such, expression of TRPA1 and 
TRPM8 should be re-analyzed in each DRG level independently.   
Evidence for alternative splicing of TRPV1 is documented in the literature; 
however, little is known about the tissue distribution or the differential expression of 
variants [6, 72]. Similar to the experiments in this project, analysis of TRPV1 splice 
variant mRNA levels in different levels of dorsal root ganglia in response to neuropathic 
pain needs to be performed.    Karl Andersen, a fellow graduate student, is currently 
investigating the TRPV1b and TRPV1β variants in rat.  Other variants have been 
identified in rat that need to be examined, including TRPV1var and TRPV15’sv. Splice 
variants of the canonical TRPM8 have also been reported in human [73].  Preliminary 
results from Candice Kruth have identified a potential TRPM8 splice variant expressed in 
rat DRG.  Analysis of the expression of TRPV1 and TRPM8 alternate forms in each 
Dorsal Root Ganglia level will further shed light on how the body encodes different types 
of pain.  The ultimate goal is to develop channel specific molecular antagonists that will 
selectively block specific types of pain. 
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APPENDIX 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix Table 1.   
 
Day 9 ∆∆Ct and fold-change data calculated by comparing each ∆Ct from an 
ipsilateral CCI DRG sample to each ∆Ct from an ipsilateral control sample at 
the same vertebral level.  Red, bold fold changes represent a mathematical 
increase in TRPV1 mRNA in CCI DRG relative to control.  Fold change was 
calculated 2(∆∆Ct±SEM). 
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(Appendix Table 1 Continued) 
 
 
 
 
 
 
 
 
 
 
 
                                                                                                                                           B. Zeyzus Johns 
74 
 
 
 
 
 
 
 
 
 
 
 
Appendix Table 2. 
 
Day 12 ∆∆Ct and fold-change data calculated by comparing each ∆Ct from an 
ipsilateral CCI DRG sample to each ∆Ct from an ipsilateral control sample at 
the same vertebral level.  Red, bold fold changes represent an increase in 
TRPV1 mRNA in CCI DRG relative to control.  Fold change was calculated 
2(∆∆Ct±SEM). 
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(Appendix Table 2 Continued) 
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Appendix Table 3.   
 
All ∆∆Ct and fold-change data calculated by comparing each ∆Ct from an 
ipsilateral DRG sample to each ∆Ct from a contralateral DRG sample at the 
same vertebral level in the same animal.  Red, bold fold changes represent a 
mathematical increase in TRPV1 mRNA in ipsilateral DRG relative to 
contralateral.  Fold change was calculated 2(∆∆Ct±SEM). 
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(Appendix Table 3 Continued) 
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(Appendix Table 3 Continued) 
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CCI Neuropathy 
Day 8 Post-Operative 
    
Rat Guarding Paw Licking Paw Lifting 
1 X X X 
2 X --- X 
3 --- --- X 
4 --- X X 
5 --- X X 
6 --- --- X 
    
Day 11 Post-Operative 
    
Rat Guarding Paw Licking Paw Lifting 
1 X X X 
2 X X X 
3 --- --- --- 
    
    
Sham Control 
Day 8 Post-Operative    
    
Rat Guarding Paw Licking Paw Lifting 
1 --- --- --- 
2 --- X --- 
3 --- --- --- 
4 --- --- --- 
5 --- --- --- 
6 --- --- --- 
    
Day 11 Post-Operative    
    
Rat Guarding Paw Licking Paw Lifting 
1 --- --- --- 
2 --- --- --- 
3 --- --- --- 
    
    
Un-operated Control 
Day 8 Post-Operative    
    
Rat Guarding Paw Licking Paw Lifting 
Appendix Table 4.  Nocifensor Behaviors Recorded During the 
Mechanical Pain Assessment. 
 
 Nocifensor behaviors were recorded for each rat during the mechanical pain 
assessment.  Guarding refers to contact avoidance between the affected (right) 
hind limb and the wire mesh floor.  The occurrence of paw licking was recorded 
for the right hind paw after application of the pain stimulus.  Paw lifting refers to 
the rat holding its affected hind paw above the testing surface after application of 
the stimulus (5-10s).  X = positive for the pain behavior. 
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1 
2 
--- 
--- 
--- 
--- 
--- 
--- 
3 --- --- --- 
4 --- X --- 
5 --- --- --- 
6 --- --- --- 
    
Day 11 Post-Operative    
    
Rat Guarding Paw Licking Paw Lifting 
1 --- --- --- 
2 --- --- --- 
3 --- --- --- 
(Appendix Table 4 Continued) 
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CCI Neuropathy 
Day 8 Post-Operative 
    
Rat Guarding Paw Licking Paw Lifting 
1 X X X 
2 X X --- 
3 --- X --- 
4 --- --- --- 
5 X --- X 
6 X --- --- 
    
Day 11 Post-Operative 
    
Rat Guarding Paw Licking Paw Lifting 
1 X X --- 
2 --- X X 
3 --- X X 
    
    
Sham Control 
Day 8 Post-Operative    
    
Rat Guarding Paw Licking Paw Lifting 
1 --- X --- 
2 --- --- --- 
3 --- X --- 
4 --- X --- 
5 --- --- --- 
6 --- --- --- 
    
Day 11 Post-Operative    
    
Rat Guarding Paw Licking Paw Lifting 
1 --- --- --- 
2 --- --- --- 
3 --- --- --- 
    
    
Un-operated Control 
Day 8 Post-Operative    
    
Rat Guarding Paw Licking Paw Lifting 
Appendix Table 5.  Nocifensor Behaviors Recorded During the 
Thermal Pain Assessment. 
 
 Nocifensor behaviors were recorded for each rat during the thermal pain 
assessment.  Guarding refers to contact avoidance between the affected (right) 
hind limb and the heated testing surface.  The occurrence of paw licking was 
recorded in the right hind paw after heat irradiation.  Paw lifting refers to the rat 
holding its affected hind paw above the testing surface after application of the 
stimulus (5-10s).  X = positive for the pain behavior. 
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1 
2 
--- 
--- 
X 
--- 
--- 
--- 
3 --- --- --- 
4 --- --- --- 
5 --- --- --- 
6 --- --- --- 
    
Day 11 Post-Operative    
    
Rat Guarding Paw Licking Paw Lifting 
1 --- --- --- 
2 --- --- --- 
3 --- --- --- 
(Appendix Table 5 Continued) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
